RS49523B - Vodeni farmaceutski rastvor - Google Patents

Vodeni farmaceutski rastvor

Info

Publication number
RS49523B
RS49523B YU69096A YU69096A RS49523B RS 49523 B RS49523 B RS 49523B YU 69096 A YU69096 A YU 69096A YU 69096 A YU69096 A YU 69096A RS 49523 B RS49523 B RS 49523B
Authority
RS
Serbia
Prior art keywords
zinc
magnesium
compound
pharmaceutical solution
watery
Prior art date
Application number
YU69096A
Other languages
English (en)
Inventor
Alan Wayne Boettner
Connor Peter Canning
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU69096A publication Critical patent/YU69096A/sh
Publication of RS49523B publication Critical patent/RS49523B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Vodeni farmaceutski rastvor, naznačen time, što uključuje danofloksacin u količini od oko 60 do 200 mg/ml ili njegovu farmaceutski prihvatljivu so, i (1) jedinjenje magnezijuma, ili (2) smešu jedinjenja cinka sa korastvaračem, pri čemu je jedinjenje magnezijuma magnezijumoksid ili magnezijumhlorid, gde je molarni odnos magnezijuma prema danofloksacinu ili njegovoj soli od oko 0,25 do oko 2, a jedinjenje cinka je cinkoksid ili cinkacetat, gde je molarni odnos cinka prema aktivnom jedinjenju od oko 0,3 do oko 0,7. Prijava sadrži još 6 zavisnih patentnih zahteva.
YU69096A 1995-12-21 1996-12-20 Vodeni farmaceutski rastvor RS49523B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (2)

Publication Number Publication Date
YU69096A YU69096A (sh) 1999-06-15
RS49523B true RS49523B (sr) 2006-10-27

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
YU69096A RS49523B (sr) 1995-12-21 1996-12-20 Vodeni farmaceutski rastvor

Country Status (42)

Country Link
US (1) US5811130A (sr)
EP (1) EP0868183B1 (sr)
JP (1) JP3416145B2 (sr)
KR (1) KR100402570B1 (sr)
CN (1) CN1104899C (sr)
AP (1) AP706A (sr)
AR (1) AR005147A1 (sr)
AT (1) ATE212551T1 (sr)
AU (1) AU709474B2 (sr)
BG (1) BG63933B1 (sr)
BR (1) BR9612230A (sr)
CA (1) CA2239352C (sr)
CO (1) CO4480098A1 (sr)
CZ (1) CZ293747B6 (sr)
DE (1) DE69618987T2 (sr)
DK (1) DK0868183T3 (sr)
DZ (1) DZ2146A1 (sr)
EG (1) EG24071A (sr)
ES (1) ES2167609T3 (sr)
GT (1) GT199600098A (sr)
HR (1) HRP960607B1 (sr)
HU (1) HU227918B1 (sr)
IL (1) IL124454A (sr)
IS (1) IS2010B (sr)
MA (1) MA24035A1 (sr)
MX (1) MX9805026A (sr)
MY (1) MY117109A (sr)
NO (1) NO315734B1 (sr)
NZ (2) NZ501160A (sr)
OA (1) OA10697A (sr)
PE (1) PE25798A1 (sr)
PL (1) PL186795B1 (sr)
PT (1) PT868183E (sr)
RS (1) RS49523B (sr)
RU (1) RU2141827C1 (sr)
SI (1) SI0868183T1 (sr)
SK (1) SK284412B6 (sr)
TN (1) TNSN96163A1 (sr)
TW (1) TW449475B (sr)
UA (1) UA56151C2 (sr)
WO (1) WO1997023217A1 (sr)
ZA (1) ZA9610780B (sr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
JP2005535644A (ja) * 2002-06-26 2005-11-24 ファルマシア コーポレイション 安定な非経口パレコキシブ液体製剤
ZA200700844B (en) * 2004-07-02 2009-07-29 Daiichi Seiyaku Co Quinolone-containing medicinal composition
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
LT1991201T (lt) * 2006-02-10 2018-07-25 Pari Pharma Gmbh Puškiami antibiotikai inhaliaciniam gydymui
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
RU2019128568A (ru) * 2017-02-13 2021-03-15 Байер Энимэл Хельс ГмбХ Жидкая композиция, содержащая прадофлоксацин
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
AU647772B2 (en) * 1989-12-29 1994-03-31 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HU227918B1 (en) 2012-06-28
WO1997023217A1 (en) 1997-07-03
PL328001A1 (en) 1999-01-04
UA56151C2 (uk) 2003-05-15
PE25798A1 (es) 1998-05-21
CN1104899C (zh) 2003-04-09
TW449475B (en) 2001-08-11
ATE212551T1 (de) 2002-02-15
US5811130A (en) 1998-09-22
AU7328996A (en) 1997-07-17
YU69096A (sh) 1999-06-15
HUP9903726A2 (hu) 2000-04-28
NZ320545A (en) 2000-03-27
OA10697A (en) 2001-05-04
DE69618987D1 (de) 2002-03-14
DZ2146A1 (fr) 2002-10-23
BG102542A (en) 1999-06-30
RU2141827C1 (ru) 1999-11-27
NZ501160A (en) 2001-10-26
ES2167609T3 (es) 2002-05-16
AP9600898A0 (en) 1997-01-31
IS4755A (is) 1998-05-25
NO982842D0 (no) 1998-06-19
NO982842L (no) 1998-06-19
MA24035A1 (fr) 1997-07-01
SK284412B6 (sk) 2005-03-04
KR19990076617A (ko) 1999-10-15
BG63933B1 (bg) 2003-07-31
JPH11501331A (ja) 1999-02-02
NO315734B1 (no) 2003-10-20
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
HRP960607A2 (en) 1998-06-30
DE69618987T2 (de) 2002-11-21
MY117109A (en) 2004-05-31
CA2239352A1 (en) 1997-07-03
IL124454A0 (en) 1998-12-06
CZ193098A3 (cs) 1999-05-12
JP3416145B2 (ja) 2003-06-16
SI0868183T1 (en) 2002-04-30
DK0868183T3 (da) 2002-03-25
ZA9610780B (en) 1998-06-22
GT199600098A (es) 1998-06-12
TNSN96163A1 (fr) 2005-03-15
MX9805026A (es) 1998-09-30
CO4480098A1 (es) 1997-07-09
PL186795B1 (pl) 2004-02-27
BR9612230A (pt) 1999-07-13
HRP960607B1 (en) 2002-06-30
EP0868183B1 (en) 2002-01-30
EP0868183A1 (en) 1998-10-07
CZ293747B6 (cs) 2004-07-14
AR005147A1 (es) 1999-04-14
HUP9903726A3 (en) 2001-01-29
CA2239352C (en) 2002-06-04
IL124454A (en) 2003-10-31
IS2010B (is) 2005-05-13
SK80798A3 (en) 1999-09-10
EG24071A (en) 2008-05-11
PT868183E (pt) 2002-06-28
CN1205636A (zh) 1999-01-20
KR100402570B1 (ko) 2003-12-18

Similar Documents

Publication Publication Date Title
RS49523B (sr) Vodeni farmaceutski rastvor
SE9503143D0 (sv) New preparation
ATE100708T1 (de) Unbeschichtete pharmazeutische reaktionstablette.
CA2354057A1 (en) Sustained release tablet containing hydrocolloid and cellulose ether
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
HUP9901319A2 (hu) 9-Hidroxi-riszperidon zsírsavészterek vizes szuszpenziói, előállításuk és alkalmazásuk
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
EP0244178A3 (en) Intraocular dosage compositions and method of use
BR0109091A (pt) Formulações de ranolazina de liberação sustentada
PT814782E (pt) Composicao farmaceutica estabilizada com um agente basico
CA2342390A1 (en) Sustained release ranolazine formulations
CA2193129A1 (en) Transdermal drug delivery system
GB2264640B (en) Microcrystalline cellulose spheroids comprising hydromorphone and a sugar
DE69812949D1 (de) Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
MD872G2 (ro) Compoziţie farmaceutică efervescentă şi preparat pe baza ei, procedeu de fabricare a preparatului
RS50445B (sr) Farmaceutski rastvori levosimendana
WO1993013739A3 (en) Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
AU2001291731A1 (en) Pharmaceutical, effervescent formulation containing ramipril
TR199801126T2 (xx) Tolfenamik asit veya bunun farmas�tik a��dan kabul edilebilir bir tuzunu i�eren h�zl� tahliye edici tablet.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.